1. Home
  2. CTNM
  3. CTNM News

Latest Contineum Therapeutics Inc. Class A Common Stock (CTNM) News on December 18, 2024

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
CTNM

Business Wire

2 days ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
CTNM

Business Wire

23 days ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
CTNM

Business Wire

a month ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation
CTNM

Simply Wall St.

a month ago

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Contineum Therapeutics to Attend Upcoming Investor Conferences
CTNM

Business Wire

a month ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
CTNM

Business Wire

a month ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%
CTNM

Simply Wall St.

2 months ago

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
CTNM

Business Wire

4 months ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
CTNM

Business Wire

4 months ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

CTNM

Business Wire

5 months ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
CTNM

Business Wire

6 months ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

CTNM

Business Wire

6 months ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
CTNM

Business Wire

6 months ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

CTNM

Business Wire

7 months ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
CTNM

Business Wire

7 months ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

CTNM

GlobeNewswire

8 months ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

Share on Social Networks: